Crystal structures of penicillin-binding protein 3 in complexes with azlocillin and cefoperazone in both acylated and deacylated forms

Jingshan Ren1, Joanne E. Nettleship1,2, Alexandra Males1,2, David I. Stuart1,3 and Raymond J. Owens1,2

1 Division of Structural Biology, Henry Wellcome Building for Genomic Medicine, University of Oxford, Oxford, UK
2 OPPF-UK, The Research Complex at Harwell, Rutherford Appleton Laboratory, Oxfordshire, UK
3 Diamond Light Sources, Harwell Science and Innovation Campus, Didcot, UK

Correspondence
R. J. Owens and J. Ren, Division of Structural Biology, Henry Wellcome Building for Genomic Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
Fax: +44 (0) 1235 567799
Tel: +44 (0) 1235 567700
E-mail: ray@strubi.ox.ac.uk
Fax: +44 (0) 1865 287501
Tel: +44 (0) 1865 287500
E-mail: ren@strubi.ox.ac.uk

Penicillin-binding protein 3 (PBP3) from Pseudomonas aeruginosa is the molecular target of β-lactam-based antibiotics. Structures of PBP3 in complexes with azlocillin and cefoperazone, which are in clinical use for the treatment of pseudomonad infections, have been determined to 2.0 Å resolution. Together with data from other complexes, these structures identify a common set of residues involved in the binding of β-lactams to PBP3. Comparison of wild-type and an active site mutant (S294A) showed that increased thermal stability of PBP3 following azlocillin binding was entirely due to covalent binding to S294, whereas cefoperazone binding produces some increase in stability without the covalent link. Consistent with this, a third crystal structure was determined in which the hydrolysis product of cefoperazone was noncovalently bound in the active site of PBP3. This is the first structure of a complex between a penicillin-binding protein and cephalosporic acid and may be important in the design of new noncovalent PBP3 inhibitors.

Keywords: azlocillin; cefoperazone; penicillin-binding protein; Pseudomonas aeruginosa; thermal shift assay; β-lactam antibiotics
the permeability of the outer membrane and mutation of residues in the active site of PBPs [8,9]. The levels of expression of PBPs differ between β-lactam resistant bacterial strains, however, this variation does not appear to be linked to resistance development [10].

Azlocillin (Fig. 1A) is representative of a group of ampicillin derivatives in which the α-amino side group has been replaced with urea analogues and which are active against P. aeruginosa (MIC<sub>50</sub> 50 μg·mL<sup>-1</sup>) [11]. Cefoperazone (Fig. 1B), also known as cefobid, is a third-generation cephalosporin [12] and is one of a small number of cephalosporin that are effective in treating Pseudomonas bacterial infections (MIC<sub>50</sub> 25 μg·mL<sup>-1</sup>) [13]. We have previously reported structures of PBP3 acyl-enzyme complexes (AECs) with β-lactams of both penicillin and cephalosporin classes as well as a structure of PBP3 in complex with (5S)-penicilloic acid (PA), a product of deacylated PBP3–piperacillin AEC [2,14]. In order to gain insight into the binding modes of azlocillin and cefoperazone, we have determined the crystal structures of PBP3 from P. aeruginosa in complexes with azlocillin and cefoperazone. The structure of the PBP3–azlocillin complex shows the ring-opened β-lactam intermediate covalently bound to S294. For the PBP3–cefoperazone complex, two different crystal structures were obtained. In one case, similar to the azlocillin complex, the cefoperazone (introduced by soaking) forms a covalent intermediate to the catalytic S294 of the active site. In the second structure, the ester-linkage of cefoperazone with S294 is hydrolysed during the crystallization process and the product of the reaction, anhydrodesacetyl cephalosporic acid (ACA), is observed bound in the active site. Similarities and differences between the three antibiotic bound structures and related ones are discussed.

**Materials and methods**

**Protein production and crystallization**

The soluble domain of PBP3 (residues 35-579) was produced using the method of Sainsbury et al. [2]. Briefly, PBP3 inserted into the vector, pOPINF [15], which introduces a N-terminal hexahistidine tag separated by a rhinovirus 3C protease cleavage site, was expressed in Escherichia coli Rosetta<sup>™</sup> 2(DE3) cells grown in auto-induction media [16]. Cells were lysed and protein purified from

---

**Fig. 1.** Chemical structures of β-lactams and their hydrolysis products. (A) azlocillin, (B) cefoperazone and (C) piperacillin and their hydrolysis products (D), (E) and (F) respectively.
the soluble fraction using nickel affinity followed by size exclusion chromatography in 20 mM Tris pH 7.5, 200 mM NaCl. Fractions containing PBP3 were combined and concentrated prior to use.

Crystallization screening experiments were performed with PBP3 at 4.3 mg·mL\(^{-1}\) in 200 nL volume sitting drops by vapour diffusion as previously described [17]. Two types of PBP3 crystals were obtained, (a) in the presence of 0.5 mM azlocillin in a standard three row optimization of 2.5 mM NaCl; 0.1 mM imidazole pH 8.0 (Emerald Wizard 1 & 2 screen, condition D1) using the method of Walter et al. [17]; (b) with the addition of 0.5 mM cefoperazone in 1.26 M \((\text{NH}_4)_2\text{SO}_4; 0.1\text{ M CHES pH 9.5; 0.2 M NaCl (Emerald Wizard 1 & 2 screen, condition G5). Diffraction data were collected 9 days following setting up drops of protein and azlocillin showed no binding of the \(\beta\)-lactam in the active site (data not shown). The structure was essentially identical to the apo structure reported previously [2,8]. Diffraction data were then collected from crystals that had additionally been soaked with azlocillin prior to data collection, and the electron density map showed clearly that the azlocillin had formed an acyl–enzyme complex (AEC) with PBP3 (Fig. 2B).

The structure of PBP3 (Fig. 2A) can be divided into two domains, an N-terminal domain (residues 35-218) and a transpeptidase domain (residues 219-579) (Fig. 2A). The N-terminal domain is very flexible, often associated with weak electron density, especially for the loop regions in all our PBP3 structures of three different crystal forms [2,14]. A helical region towards the N terminus, called the head subdomain, is highly conserved among class B PBPs and is thought to be involved in cell wall synthesis through interactions with parts of the divisome [24]. The N-terminal domain also plays a role in stabilizing the folding of the transpeptidase domain [25]. The transpeptidase domain folds to produce a central core of five anti-parallel \(\beta\)-sheets, \(\beta_1-\beta_5\), with \(\beta_3\) lining the top of the active site and \(\beta_4, \beta_2, \alpha_4, \alpha_5, \alpha_8\) and \(\alpha_{11}\) (Fig. 2A) surrounding the substrate-binding cleft which is wide enough to accommodate two peptido-glycan stems.

There are three conserved motifs found in the active site among all types of PBPs, SXXK, SXN and KSGT which are important in the catalysis [26]. In PBP3, the SXXK motif is composed of S294, T295, V296 and K297, from the N terminus of \(\alpha_2\) and located at the base of the cleft. In the PBP3–azlocillin AEC, the \(\beta\)-lactam is covalently bound to the hydroxyl of the nucleophilic S294 via an ester-linkage as observed in other PBP3–\(\beta\)-lactam AECs [2]. S349 and N351 from the SXN motif interact with the inhibitor via hydrogen bonds to the nitrogen of the thiazolidine ring and C-9 carbonyl oxygen respectively (Fig. 3A). The third motif, KSGT, composed of residues 484-487, orients the thiazolidine ring by hydrogen bonding the carboxylate group via the side-chains of S485 and T487. The hydrogen bonds contributed from the backbone nitrogen and carbonyl oxygen of T487 and the

**Results and Discussion**

**The structure of the PBP3–azlocillin complex**

PBP3 (residues 35-579) was produced as previously described [2]. Attempts to produce crystals of the PBP3–azlocillin complex by cocrystallization were unsuccessful. Diffraction data collected from crystals, 9 days following setting up drops of protein and azlocillin showed no binding of the \(\beta\)-lactam in the active site (data not shown). The structure was essentially identical to the apo structure reported previously [2,8]. Diffraction data were then collected from crystals that had additionally been soaked with azlocillin prior to data collection, and the electron density map showed clearly that the azlocillin had formed an acyl–enzyme complex (AEC) with PBP3 (Fig. 2B).

The structure of PBP3 (Fig. 2A) can be divided into two domains, an N-terminal domain (residues 35-218) and a transpeptidase domain (residues 219-579) (Fig. 2A). The N-terminal domain is very flexible, often associated with weak electron density, especially for the loop regions in all our PBP3 structures of three different crystal forms [2,14]. A helical region towards the N terminus, called the head subdomain, is highly conserved among class B PBPs and is thought to be involved in cell wall synthesis through interactions with parts of the divisome [24]. The N-terminal domain also plays a role in stabilizing the folding of the transpeptidase domain [25]. The transpeptidase domain folds to produce a central core of five anti-parallel \(\beta\)-sheets, \(\beta_1-\beta_5\), with \(\beta_3\) lining the top of the active site and \(\beta_4, \beta_2, \alpha_4, \alpha_5, \alpha_8\) and \(\alpha_{11}\) (Fig. 2A) surrounding the substrate-binding cleft which is wide enough to accommodate two peptido-glycan stems.

There are three conserved motifs found in the active site among all types of PBPs, SXXK, SXN and KSGT which are important in the catalysis [26]. In PBP3, the SXXK motif is composed of S294, T295, V296 and K297, from the N terminus of \(\alpha_2\) and located at the base of the cleft. In the PBP3–azlocillin AEC, the \(\beta\)-lactam is covalently bound to the hydroxyl of the nucleophilic S294 via an ester-linkage as observed in other PBP3–\(\beta\)-lactam AECs [2]. S349 and N351 from the SXN motif interact with the inhibitor via hydrogen bonds to the nitrogen of the thiazolidine ring and C-9 carbonyl oxygen respectively (Fig. 3A). The third motif, KSGT, composed of residues 484-487, orients the thiazolidine ring by hydrogen bonding the carboxylate group via the side-chains of S485 and T487. The hydrogen bonds contributed from the backbone nitrogen and carbonyl oxygen of T487 and the
nitrogen of R489 to the carbonyl oxygen of the ester-linkage. N8 amino group and C12 carbonyl oxygen of the inhibitor, respectively, mimic the interactions between two antiparallel $\beta$-strands as observed in the piperacillin acyl–enzyme complex [14] (Fig. 4A). In fact, the binding mode of azlocillin is very similar to that of piperacillin which also has a thiazolidine ring. However, the smaller oxoimidazolidin ring in azlocillin lacks the direct hydrogen bond to Y328 and makes weaker ring-stacking interactions with Y409 and Y498 compared to the dioxopiperazine of piperacillin (PDB 4KQO and Fig. 4A).

**Structure of the PBP3–cefoperazone complex**

The structure of PBP3–cefoperazone covalent complex was obtained by soaking a type (a) crystal with cefoperazone prior to data collection (Table 1). Examination of the acyl complex structure shows that the 1-methyl-5-thiotetrazole group [27] of cefoperazone (Fig. 1) has been released during the catalytic opening of the $\beta$-lactam ring (Fig. 2C). This leaves a double bonded methylene group on the end of the thiazine ring which is observed in the structure of PBP3 with well-defined electron density (Fig. 2C). The release of 1-methyl-5-thiotetrazole into the bloodstream following administration of cefoperazone can lead to hypoprothrombinemia. This is the result of the inhibition by 1-methyl-5-thiotetrazole of glutamic acid $\gamma$-carboxylation, a vitamin K-dependent reaction required for the formation of active clotting factors [28].

The active site structure of PBP3–cefoperazone covalent complex is very similar to that of PBP3–azlocillin, with the positions of C$\alpha$ atoms of the key active
site residues varying by less than 0.2 Å between the two acyl complexes (Fig. 3A,B), and most of the protein-inhibitor hydrogen bond interactions are conserved between them (Table 2). However, there are key differences that reflect the different chemical structures of the two antibiotics (Fig. 1). The six-membered thiazine ring derived from cefoperazone has a methylene group at the C-3 position rather than the dimethyl group of the penicillin-derived five-membered thiazolidine ring in azlocillin. This methylene group interacts with the side-chain of F533 so that the phenyl ring of F533 rotates by ~70° towards the methylene group. This is not observed in the azlocillin acyl–enzyme complex (Fig 3A). Cefoperazone also has a hydroxyphenyl ring enabling hydrogen bonding to Y532, whereas azlocillin has a phenyl ring and so it does not interact with the hydroxyl of Y532. Cefoperazone has a larger dioxopiperazine ring, in contrast to the oxoimidazolidin ring in azlocillin, making tighter off-centre parallel and T-shaped ring-stacking interactions with Y409 and Y498 respectively (Fig. 3B). In addition, the larger size of the dioxopiperazine ring means that one of its oxygen atoms can form a direct hydrogen bond to the hydroxyl group of Y328 (2.9 Å). The ring structure of the β-lactam at this position in both structures stabilizes Y498 and the whole β3-β4 loop which are disordered in all published PBP3 covalent complexes with smaller β-lactams [2,8]. Cefoperazone is closely related in structure to piperacillin principally differing as with azlocillin in the lactam ring (Fig1). Superimposition of the covalent complexes between PBP3–cefoperazone and PBP3–piperacillin (PDB id 4KQO) shows that the two acyl complexes are very similar (Fig. 4B). The main difference is the orientation of F533 which is rotated in the cefoperazone complex compared to both the piperacillin and azlocillin covalent complexes (Fig. 4A). As previously described for other β-lactams, covalent binding of azlocillin and cefoperazone is associated with a narrowing of the substrate-binding cleft. Comparing both the azlocillin and cefoperazone PBP3 acyl complexes with previously published structures [2,8,14] shows that a common set of residues are involved in the biding of a different β-lactams to PBP3 (Table 2).

Structure of the PBP3–anhydrodesacetyl cephalosporic acid complex

Cocrystallization of PBP3 with cefoperazone produced crystals of the deacylated product of the antibiotic, anhydrodesacetyl cephalosporic acid (ACA), bound in the active site (Figs 2D and 3C). Comparison of the structures of the PBP3–cefoperazone covalent complex

Fig. 3. Details of protein-inhibitor interactions. (A) azlocillin and (B) cefoperazone PBP3 covalent complexes, (C) PBP3–anhydrodesacetyl cephalosporic (ACA) noncovalent complex. The protein backbone is shown as ribbons in rainbow colours from the N to C terminus. Key protein side-chains are drawn as cyan sticks. The antibiotics are shown as grey sticks with nitrogen atoms in blue, oxygen atoms in red and sulfur atoms in yellow. The red spheres are water molecules. Potential hydrogen bonds are indicated by yellow dashed lines.
and the product complex showed that deacylation of the S294 does not affect the overall structure of PBP3, in particular the transpeptidase domain. In fact, the conformation of only a few key and conserved residues in the active site is altered between the two complexes (Fig. 4C). Notably, the position of the thiazine ring has changed significantly upon deacylation, shifted by ~2 Å away from S294 (Fig. 4C), whereas the piperazine ring remains almost unchanged. The movement of the thiazine ring is associated with rotation of F533 by about 50° anticlockwise. This avoids clashes and enables the carboxylate (which has rotated 90°) to cap the N terminus of α11 via a direct hydrogen bond to the amino group of G535 rather than via a water molecule as seen in the covalent complex (Fig. 3B). The side-chain of S294 rotated 120° upon deacylation, makes bifurcated hydrogen bonds to the side-chain of K484 and the carbonyl oxygen of S485 while maintaining a tight hydrogen bond (2.7 Å) to the carboxylate formed by ester hydrolysis of the covalent complex. This newly formed carboxylate is rotated clockwise by 45° into the same plane as the thiazine ring and no longer makes a hydrogen bond to the amino group of T487. The ethyl group on the dioxopiperazine ring has rotated 55° towards Y328, the side-chain of which becomes disordered (Fig. 3B,C).

Fig. 4. Comparison of covalent and noncovalent PBP3 complexes (A) Superposition of PBP3–azlocillin and PBP3–piperacillin (PDB id 4KQO) covalent complexes, (B) PBP3–cefoperazone and PBP3–piperacillin covalent complexes. (C) PBP3–cefoperazone and PBP3–anhydrodesacetyl cephalosporic (ACA) complexes and (D) PBP3–ACA and PBP3–PA (PDB id 4KQR) complexes. In (A–C), the protein side-chains in the azlocillin and cefoperazone acyl complexes are shown as thick cyan sticks and β-lactams as thick grey sticks, the inhibitor and protein side-chains in the piperacillin acyl complex and the PBP3-ACA complex are shown as thinner sticks. The side-chains and the inhibitor of PBP3-ACA complex are shown as thick sticks in (D).
Comparison of PBP3–anhydrodesacetyl cephalosporic and PBP3–penicilloic complexes

There is one other report of PBP3 from *P. aeruginosa* noncovalently bound to a deacylated β-lactam product, namely (5S)-penicilloic acid (PA). In this case the complex was obtained by both cocrystallization of PBP3 with piperacillin and crystal soaking with the reaction product of piperacillin and a metallo-β-lactamase. In the PBP3–ACA structure, the thiazine ring is a (6R) epimer (Figs 1 and 4D) consistent with all other reported PBP3–β-lactam covalent complexes.

Table 1. X-ray data collection and refinement statistics.

| Data set                  | PBP3–azlocillin | PBP3–cefoperazone | PBP3–ACA |
|---------------------------|-----------------|-------------------|----------|
| X-ray source              | Diamond I04-1   | Diamond I04-1     | Diamond I02 |
| Wavelength (Å)            | 0.91730         | 0.91730           | 0.97960  |
| Space group               | P1              | P1                | C2       |
| Cell dimensions (Å, °)    | 57.3, 74.9, 82.7, 71.3, 86.0, 85.7 | 57.2, 74.4, 82.4, 71.7, 86.1, 85.9 | 176.9, 41.3, 87.8, 90, 117.4, 90 |
| Resolution (Å)            | 50.0–2.00 (2.07–2.00) | 50.0–2.00 (2.07–2.00) | 30.0–2.70 (2.80–2.70) |
| Unique reflections        | 76 005 (6889)   | 86 608 (7921)     | 15 866 (1552) |
| Rmerge                    | 0.137 (0.579)   | 0.190 (0.641)     | 0.092 (0.722) |
| Completeness (%)          | 86.7 (78.3)     | 92.8 (90.7)       | 100 (100) |
| Redundancy                | 2.7 (2.4)       | 3.4 (2.9)         | 3.7 (3.7) |

Refinement

| Resolution (Å)            | 50.0–2.00       | 50.0–2.00         | 50.0–2.70 |
| No. reflections           | 72 141/3800     | 76 519/4066       | 15 052/789 |
| R factor: (Rwork/Rfree)a  | 0.198/0.237     | 0.226/0.263       | 0.202/0.249 |
| No. of atoms (protein/water/other) | 7644/411/96 | 7638/605/110 | 3908/25/38 |
| B-factors (Å)             | 47/44/42        | 35/39/33          | 66/49/75  |
| R.m.s. deviations         | Bond lengths (Å) | Bond angles (°)   | 90.7 | 90.6 | 86.8 |
| Ramachandran Plot         | 90.7            | 90.6              | 12.7 |
| Favoured (%)              | 93.5           | 9.4               | 0.5 |
| Allowed (%)               | 0              | 0                 | 0 |
| Outliers (%)              | 0              | 0                 | 0 |

* Rwork and Rfree are defined by \( R = \frac{\sum_{hk} |F_{\text{obs}}| - |F_{\text{calc}}|}{\sum_{hk} |F_{\text{obs}}|} \), where \( h,k,l \) are the indices of the reflections (used in refinement for Rwork; 5%, not used in refinement, for Rfree), \( F_{\text{obs}} \) and \( F_{\text{calc}} \) are the structure factors, deduced from measured intensities and calculated from the model respectively.

Table 2. Summary of hydrogen bond interactions in PBP3–β-lactam AECs and deacylated product complexes.

| Inhibitor | Hydrogen bonds (≤ 3.2 Å) | PDB id | Reference |
|-----------|---------------------------|--------|-----------|
| Carbenicillin | N-S294, OG-S349, ND2-N351, OH-Y409, OG-S485, OG1-T487, N-T487, O-T487 | 3OCL | Sainsbury et al. [2] |
| Azlocillin  | N-S294, OG-S349, ND2-N351, OH-Y409, OG-S485, OG1-T487, N-T487, O-T487, N-R489 | 5DF7 | This paper |
| Piperacillin | N-S294, OH-Y328, OG-S349, ND2-N351, OH-Y409, OG-S485, OG1-T487, N-T487, O-T487, N-R489 | 4KOO | van Berkel et al. [14] |
| Cefoperazone | N-S294, OH-Y328, OG-S349, ND2-N351, OH-Y409, OG-S485, OG1-T487, N-T487, O-T487, N-R489, OH-Y532 | 4KQO | van Berkel et al. [14] |
| Ceftazidime | OE2-E291, N-S294, OG-S349, ND2-N351, NZ-K484, OG-S485, OG1-T487, N-T487, O-T487, N-R489, OH-R489, NH1-R489 | 3OCN | Sainsbury et al. [2] |
| Aztreonam   | OE1-E291, N-S294, OG-S349, ND2-N351, S485, NZ-K484, OG-S485, OG1-T487, N-T487, O-T487, N-R489, NE-R489 | 3PBS | Han et al. [8] |
| ACA         | OG-S294, OG-S349, ND2-N351, OH-Y409, OG-S485, OG1-T487, O-T487, N-R489, OH-Y532, N-G535 | 5DF9 | This paper |
| (5S)-PA     | OG-S294, OG-S349, ND2-N351, OH-Y409, OG-S485, OG1-T487, N-T487, O-T487, N-R489, N-G535 | 4KOR | van Berkel et al. [14] |
[2,8,14]. By contrast, the thiazolidine in the PBP3–PA noncovalent complex is the (S5) epimer (Figs 1 and 4D). It was previously shown that hydrolysis of piperacillin catalysed either by PBP3 or a metallo-β-lactamase initially results in (S5)-PA, which was gradually converted to (S5)-PA [14]. Therefore, in the crystallographic experiments both enantiomers of PA would have been present. However, only (S5)-PA was seen in the crystal structure. In the case of cefoperazone, only the R- enantiomer of ACA was observed noncovalently bound to PBP3. This indicates that either the ACA has not epimerized during crystallization or that the R-enantiomer preferentially binds to PBP3.

Comparing the noncovalent PBP3–ACA and PBP3–PA complexes indicates why the S-enantiomer of PA is favoured over the R-enantiomer. Thus, if the thiazolidine of PA were in a (S5) stereochemistry its dimethyl group would clash with F533, whereas (6R)-ACA is accommodated. To avoid steric clashes, the epimerization of PA also results in rotation ~80° of the carboxylate produced from the cleavage of the ester-linkage. In both the covalent PBP3-cefoperazone and PBP3–ACA noncovalent complexes, the inhibitor makes addition hydrogen bonds compared to piperacillin and PA due to differences in substituents. The hydroxyphenyl side-chain of ACA/cefoperazone forms a hydrogen bond with Y532 (Fig. 3B,C). In piperacillin and PA, the hydroxyphenyl is replaced with a phenyl side group and thus lacks this hydrogen bond interaction (Fig. 4B,D).

The observations that cocrystallization of PBP3 with azlocillin did not give a complex and the acyl complex could be obtained by crystal soaking suggest that the azlocillin covalent complex can be deacylated by PBP3. Interestingly, it did not prove possible to capture the structure of PBP3 with the ester-linkage cleaved product of azlocillin presumably due to more rapid dissociation of the product compared to piperacillin and cefoperazone. This could be due to the dimethyl group on the thiazolidine ring and its smaller oxoimidazolidin group which reduce the affinity of the product to PBP3.

Examination of both noncovalent complexes suggests that binding could be increased by building into pockets in the structure. Thus, next to the methylene group of the ACA thiazine ring (dimethyl group of PA thiazolidine ring), a large space surrounded by N terminus of α11 and C-termini of α4 and α10 is not occupied. This space can be targeted by addition of a chemical group to the thiadine ring of ACA or the thiazolidine ring of PA to increase the inhibitor interactions with PBP3 to make more potent non-β-lactam inhibitor.

**Thermal shift assay**

A thermal shift assay was used to assess the effect of cefoperazone and azlocillin on the melting temperature ($T_m$) of PBP3. The $T_m$ of PBP3 alone was 40 ± 1 °C (Fig. 5A). Addition of either 0.6 mM azlocillin or 0.6 mM cefoperazone resulted in positive shifts in the $T_m$ of 12 ± 1 °C and 15 ± 1 °C respectively (Fig. 5). To investigate whether this significant increase in $T_m$ resulted from the formation of the acyl complex between PBP3 and the β-lactams, the active site serine (S294) was changed to alanine and the mutated protein evaluated in the thermal shift assay. The results showed that preventing formation of the acyl complex by the S294A mutation, abolished the thermal shift due to addition of azlocillin (Fig. 5B). Thus, stabilization of PBP3 by this penicillin is entirely dependent on the formation of the acyl intermediate with S294. By contrast, a $T_m$ shift of 9 ± 1 °C was observed for S294A PBP3 in the presence of cefoperazone (Fig. 5B).

![Fig. 5. Thermal shift assay. Melt curves to compare the melting temperatures of both apo (A) PBP3 wild-type and (B) PBP3 S294A with azlocillin and cefoperazone. (A) apo PBP3 blue, $T_m$ of 40 ± 1 °C; PBP3 and azlocillin, green, $T_m$ of 52 ± 1 °C; PBP3 and cefoperazone, red, $T_m$ of 55 ± 1 °C; PBP3 (B) apo PBP3 S294A, blue, $T_m$ of 39 ± 1 °C; PBP3 S294A and azlocillin, green, $T_m$ of 39 ± 1 °C; PBP3 S294A and cefoperazone, red, $T_m$ of 48 ± 1 °C.](image-url)
indicating that other interactions in addition to the formation of an acyl complex contribute to the stabilizing effect of the compound on PBP3 (Table 2). These observations are consistent with crystallographic results obtained with PBP3 and cefoperazone for which both covalent and noncovalently bound complexes were observed.

**Conclusion**

Structural analysis of PBP3 from *P. aeruginosa* in complex with different β-lactams (penicillins, carbapenems and cephalosporins) shows that a common set of residues, including the active site serine which becomes acylated, are key for binding. Additional hydrogen bond interactions contribute to the binding of different β-lactams as determined by their substituents on the β-lactam core. In all cases binding of the inhibitors is associated with a narrowing of the substrate-binding cleft compared to the unliganded enzyme. Deacylation of the active site serine occurs over time and the crystal structures of the PBP3–ACA and PBP3–PA show that some inhibitors remain bound in the substrate-binding cleft of the enzyme. This raises the possibility of using this structural information in the design of new nonlactam inhibitors which would not be susceptible to degradation by β-lactamases and hence overcome at least one mechanism of antibiotic resistance in the treatment of *Pseudomonas* infections.

**Acknowledgements**

The OPPF-UK is funded by the Medical Research Council (grant no. MR/K018779/1). DIS is supported by the MRC (grant no. G100099) and the Wellcome Trust Centre for Human Genetics is supported by the Wellcome Trust (grant no. 090532/Z/09/Z). We thank the beam line staff at Diamond I04-1 and I02 for assistance with data collection.

**Author contributions**

JR, JN, DIS and RJO devised the study, JN and AM purified and crystallized the PBP3 complexes. JR solved the structures of the PBP3 complexes. JR and RJO analysed the results and all authors contributed to writing the paper.

**References**

1 Sauvage E, Kerff F, Terrak M, Ayala JA and Charlier P (2008) The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. *FEMS Microbiol Rev* 32, 234–258.
2 Sainsbury S, Bird L, Rao V, Shepherd SM, Stuart DI, Hunter WN, Owens RJ and Ren JS (2011) Crystal structures of penicillin-binding protein 3 from *Pseudomonas aeruginosa*: comparison of native and antibiotic-bound forms. *J Mol Biol* 405, 173–184.
3 Yoshida H, Kawai F, Obayashi E, Akashi S, Roper DI, Tame JRH and Park SY (2012) Crystal structures of penicillin-binding protein 3 (PBP3) from methicillin-resistant *Staphylococcus aureus* in the apo and cefotaxime-bound forms. *J Mol Biol* 423, 351–364.
4 Zervosen A, Sauvage E, Frere JM, Charlier P and Luxen A (2012) Development of new drugs for an old target – the penicillin binding proteins. *Molecules* 17, 12478–12505.
5 Siegel RE (2008) Emerging gram-negative antibiotic resistance: daunting challenges, declining sensitivities, and dire consequences. *Respir Care* 53, 471–479.
6 Talbot GH (2013) Beta-Lactam antimicrobials: what have you done for me lately? *Am N Y Acad Sci* 1277, 76–83.
7 Bradford PA (2001) Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev* 14, 933–951.
8 Han S, Zaniewski RP, Marr ES, Lacey BM, Tomaras AP, Evdokimov A, Miller JR and Shanmugasundaram V (2010) Structural basis for effectiveness of siderophore-conjugated monocarbaams against clinically relevant strains of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci USA* 107, 22002–22007.
9 Moya B, Zamorano L, Juan C, Ge YG and Oliver A (2010) Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 54, 3933–3937.
10 Moya B, Beciero A, Cabot G, Juan C, Zamorano L, Alberti S and Oliver A (2012) Pan-beta-lactam resistance development in *Pseudomonas aeruginosa* clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. *Antimicrob Agents Chemother* 56, 4771–4778.
11 Phaneuf D and Neu HC (1979) Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin. *Antimicrob Agents Chemother* 16, 625–630.
12 Jones RN and Barry AL (1983) Cefoperazone – a review of its anti-microbial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics. *Rev Infect Dis* 5, S108–S126.
13 Neu HC, Fu KP, Aswapokee N, Aswapokee P and Kung K (1979) Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin. *Antimicrob Agents Chemother* 16, 150–157.

296 FEBS Letters 590 (2016) 288–297 © 2016 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
van Berkel SS, Nettleship JE, Leung IKH, Brem J, Choi H, Stuart DI, Claridge TDW, McDonough MA, Owens RJ, Ren JS et al. (2013) Binding of (5S)-penicilloic acid to penicillin binding protein 3. *ACS Chem Biol* **8**, 2112–2116.

Berrow NS, Alderton D, Sainsbury S, Nettleship J, Assenberg R, Rahman N, Stuart DI and Owens RJ (2007) A versatile ligation-independent cloning method suitable for high-throughput expression screening applications. *Nucleic Acids Res* **35**, e45.

Studier FW (2005) Protein production by autoinduction in high density shaking cultures. *Protein Expr Purif* **41**, 207–234.

Walter TS, Diprose JM, Mayo CJ, Siebold C, Pickford MG, Carter L, Sutton GC, Berrow NS, Brown J, Berry IM et al. (2005) A procedure for setting up high-throughput nanolitre crystallization experiments. Crystallization workflow for initial screening, automated storage, imaging and optimization. *Acta Crystallogr D Biol Crystallogr* **61**, 651–657.

Borek D, Cymborowski M, Machius M, Minor W and Otwinowski Z (2010) Diffraction data analysis in the presence of radiation damage. *Acta Crystallogr D Biol Crystallogr* **66**, 426–436.

Vagin A and Teplyakov A (1997) MOLREP: an automated program for molecular replacement. *J Appl Cryst* **30**, 1022–1025.

Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AGW, McCoy A et al. (2011) Overview of the CCP4 suite and current developments. *Acta Crystallogr D Biol Crystallogr* **67**, 235–242.

Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* **66**, 213–221.

Emsley P, Lohkamp B, Scott WG and Cowtan K (2010) Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* **66**, 486–501.

Nettleship JE, Brown J, Groves MR and Geerlof A (2008) Methods for protein characterization by mass spectrometry, thermal shift (ThermoFluor) assay, and multicolour or static light scattering. In Methods in Molecular Biology (Kobe B, Guss M and Huber T, eds), pp. 299–318. Humana Press Inc, Totowa, NJ, USA.

Sauvage E, Derouaux A, Fraipont C, Joris M, Herman R, Rocaboy M, Schloesser M, Dumas J, Kerff F, Nguyen-Disteche M et al. (2014) Crystal structure of penicillin-binding protein 3 (PBP3) from *Escherichia coli*. *PLoS One* **9**, 11.

de Leon SR, Daniels K and Clarke AJ (2010) Production and purification of the penicillin-binding protein 3 from *Pseudomonas aeruginosa*. *Protein Expr Purif* **73**, 177–183.

Goffin C and Ghysen JM (1998) Multimodular penicillin binding proteins: an enigmatic family of orthologs and paralogs. *Microbiol Mol Biol Rev* **62**, 1079–1093.

Boyd DB (1985) Elucidating the leaving group effect in the beta-lactam ring-opening mechanism of cephalosporins. *J Org Chem* **50**, 886–888.

Kerremans AL, Lipsky JJ, Vanloon J, Gallego MO and Weinshilboun RM (1985) Cephalosporin-induced hypoprothrombinemia – possible role for thiol methylation of 1-methyltetrazole-5-thiol and 2-methyl-1,3,4-thiadiazole-5-thiol. *J Pharmacol Exp Ther* **235**, 382–388.